We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 92.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:5382A
Amarin Corporation Plc
19 July 2007
AMARIN CONCLUDES AGM
AMARIN CORPORATION PLC
LONDON, United Kingdom, July 19, 2007 Amarin Corporation plc today held its
annual general meeting in London. All twelve resolutions proposed to the meeting
were passed by the shareholders.
Contacts:
Amarin: +44 (0) 207 907 2442
Rick Stewart Chief Executive Officer
Alan Cooke Chief Financial Officer
investor.relations@amarincorp.com
Investors:
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields +1 212 838 3777
Bruce Voss +1 310 691 7100
Media:
Powerscourt +44 (0) 207 250 1446
Paul Durman
Sarah Daly
Davy:
Ivan Murphy +353 (0) 1 6796363
Fergal Meegan
About Amarin
Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system. Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.
Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.
Amarin has its primary stock market listing in the US on the Nasdaq Capital
Market ("AMRN") and secondary listings in the UK and Ireland on AIM ("AMRN") and
IEX ("H2E") respectively.
For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com.
Information on our website does not form part of this press release.
Ends.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMUKAORBSRBAAR
1 Year Amarin Chart |
1 Month Amarin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
